



FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

G-1124

SBERESFORD@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3168

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

February 25, 2004

| CERTIFICATE OF MAILING 37 C.F.R. 1.8 | |
|--|---|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below: | |
| February 25, 2004 |  |
| Date | Sharon A. Beresford |

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/665,377 entitled "OPIATE ANALOGS SELECTIVE FOR THE δ -OPIOID RECEPTOR" – William J. Welsh et al.*
Our reference: UVMO:021US
Client reference: 02UMS028


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A6, B1, and C1-C40.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UVMO:021US..

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Sharon A. Beresford
Reg. No. 52,615
Patent Agent

SAB/kmv
Encl.: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
William J. Welsh *et al.*

Serial No.: 10/665,377

Filed: September 18, 2003

For: OPIATE ANALOGS SELECTIVE FOR
THE δ -OPIOID RECEPTOR



Group Art Unit: 1624

Examiner: Unknown

Atty. Dkt. No.: UVMO:021US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 25, 2004

Date

Sharon A. Beresford

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UVMO:021US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Sharon A. Beresford
Reg. No. 52,615
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 25, 2004

Form PTO-1449 (modified)

Atty. Docket No.

UVMO:021US

Serial No.

10/665,377

List of Patents and Publications for Applicant's

Applicant

William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 18, 2003

Group:

1624

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|--------------------------|-------|-----------|---------------------|
| | A1 | 5,436,249 | 07/25/95 | Dappen <i>et al.</i> | 514 | 279 | 05/16/94 |
| | A2 | 5,922,887 | 07/13/99 | Dondio and Ronzoni | 548 | 539 | 05/20/96 |
| | A3 | 6,359,111 | 05/19/02 | Meyer and Kasina | 530 | 302 | 05/27/99 |
| | A4 | 5,298,622 | 03/29/94 | Portoghese <i>et al.</i> | 546 | 15 | 05/12/93 |
| | A5 | 5,457,208 | 10/10/95 | Portoghese and Olmsted | 546 | 35 | 06/21/93 |
| | A6 | 4,816,586 | 03/28/89 | Portoghese | 544 | 340 | 07/29/87 |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|-------------|-----------|-----------------|----------|---------|-------|-----------|--------------------|
| | B1 | WO 99/67206 | 12/29/99 | PCT | | | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C1 | Abdelhamid <i>et al.</i> , "Selective blockage of Delta opioid receptors prevents the development of morphine tolerance and dependence in mice," <i>J. Pharmacol. Exp. Ther.</i> , 258(1):299-303, 1991. |
| | C2 | Akil <i>et al.</i> , "Endogenous opioids: biology and function," <i>Annual Rev. Neurosci.</i> , 7:223-255, 1984. |
| | C3 | Ananthan <i>et al.</i> , "Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety," <i>J. Med. Chem.</i> , 41(15):2872-2881, 1998. |
| | C4 | Ananthan <i>et al.</i> , "Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans," <i>J. Med. Chem.</i> , 42(18):3527-3538, 1999. |
| | C5 | Bertolucci <i>et al.</i> , "Microdialysis of opioid peptide release from the nucleus accumbens and ventricular pallidum of the freely moving rat," <i>Neurosci. Abstr.</i> , 18L1368, 1992. |
| | C6 | Blisky <i>et al.</i> , "SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist," <i>J. Pharmacol. Exp. Ther.</i> , 273(1):359-366, 1995. |

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UVMO:021US

10/665,377

List of Patents and Publications for Applicant's

Applicant

William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 18, 2003

Group:

1624

S. Patent Documents


See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C7 | Bradbury <i>et al.</i> , "Biosynthetic origin and receptor conformation of methionine enkephalin," <i>Nature</i> , 260:165-166, 1976. |
| | C8 | Conn <i>et al.</i> , "An unusual fischer indole synthesis with 4-keto acids: an indole incorporating the terminal hydrazine nitrogen," <i>J. Org. Chem.</i> , 55(90):2908-2913, 1990. |
| | C9 | Coombs <i>et al.</i> , "Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine," <i>Anesthesiology</i> , 62(3):358-363, 1985. |
| | C10 | Cramer III <i>et al.</i> , "Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins," <i>J. of the Am. Chem. Soc.</i> , 110(18):5959-5967, 1988. |
| | C11 | Dressman and Lennernas, In: <i>Oral Drug Absorption: Prediction and Assessment (Drugs and the Pharmaceutical Sciences)</i> , Vol. 106, 2000. |
| | C12 | Foley, In: <i>Handbook of Experimental Pharmacology</i> , Herz (ed.), Vol. 104/II: Opioids II, Springer-Verlag, Berlin, 693-743, 1993. |
| | C13 | Gomes-Flores and Weber, "Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray," <i>Immunopharm.</i> , 48:145-156, 2000. |
| | C14 | Hardman and Limbird, In: <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , 10 th ed., McGraw-Hill Professional Publishing, 2001. |
| | C15 | House <i>et al.</i> , "Suppression of immune function by non-peptidic delta opioid receptor antagonists," <i>Neurosci. Lett.</i> , 198:119, 1995. |
| | C16 | Hughes <i>et al.</i> , "Identification of two related pentapeptides from the brain with potent opiate agonist activity," <i>Nature</i> , 258:577-579, 1975. |
| | C17 | Kaliszan <i>et al.</i> , "Gradient HPLC in the determination of drug lipophilicity and acidity," <i>Pure Appl. Chem.</i> , 73:1465-1475, 2001. |
| | C18 | Knapp <i>et al.</i> , "Properties of TAN-67, a nonpeptidic δ -opioid receptor agonist, at cloned human δ - and μ -opioid receptors," <i>Eur. J. Pharmacol.</i> , 291(2):129-134, 1995. |
| | C19 | Knapp <i>et al.</i> , "Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors," <i>J. Pharmacol. Exp. Ther.</i> , 277(3):1284-1291, 1996. |
| | C20 | Koob <i>et al.</i> , "Neural substrates of opiate withdrawal," <i>TINS</i> , 15(5):186-191, 1992. |

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UVMO:021US

10/665,377

List of Patents and Publications for Applicant's

Applicant

William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 18, 2003

Group:

1624

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C21 | Liao <i>et al.</i> , "De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the δ -opioid receptor," <i>J. Med. Chem.</i> , 41(24):4767-4776, 1998. |
| | C22 | Loh <i>et al.</i> , "Molecular characterization of opioid receptors," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 30:123-147, 1990. |
| | C23 | Lutz and Pfister, "Opioid receptors and their pharmacological profiles," <i>J. Receptor Res.</i> , 12(3):267-286, 1992. |
| | C24 | Martin, "Pharmacology of opioids," <i>Pharmacol. Rev.</i> , 35(4):283-323, 1983. |
| | C25 | Okawa <i>et al.</i> , "7-arylidenenaltrexones as selective $\delta 1$ opioid receptor antagonists," <i>J. Med. Chem.</i> , 41:4177-4180, 1998. |
| | C26 | Olson <i>et al.</i> , "Endogenous opiates: 1988," <i>Peptides</i> , 10:1253-1280, 1989. |
| | C27 | Pert and Snyder, "Opiate receptor: demonstration in nervous tissue," <i>Science</i> , 179(4077):1011-1014, 1973. |
| | C28 | Pfeiffer <i>et al.</i> , "Psychotomimesis mediated by κ opiate receptors," <i>Science</i> , 233(4765):774-776, 1986. |
| | C29 | Plobeck <i>et al.</i> , "New diarylmethylpiperazines as potent and selective nonpeptidic δ opioid receptor agonists with increased in vitro metabolic stability," <i>J. Med. Chem.</i> , 43(21):3887-3894, 2000. |
| | C30 | Olmsted <i>et al.</i> , "A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic κ address element to the δ antagonist, naltrindole: 5'[(N2-alkylamindino) methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists," <i>J. Med. Chem.</i> , 36:179-180, 1993. |
| | C31 | Portoghese <i>et al.</i> , "7-arylidenenaltrexones as selective $\delta 1$ opioid receptor antagonists," <i>J. Med. Chem.</i> , 41:4177-4180, 1998. |
| | C32 | Raynor <i>et al.</i> , "Pharmacological characterization of the cloned κ -, δ -, and μ - opioid receptors," <i>Molecular Pharmacol.</i> , 45:330-334, 1994. |
| | C33 | Reid <i>et al.</i> , "Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation," <i>Life Sci.</i> , 52:PL67-71, 1993. |
| | C34 | Saltzman, In: <i>Drug Delivery: Engineering Principles for Drug Therapy (Topics in Chemical Engineering)</i> , Oxford University Press, 2001. |

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UVMO:021US

10/665,377

List of Patents and Publications for Applicant's

Applicant

William J. Welsh *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 18, 2003

Group:

1624

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C35 | Schiller <i>et al.</i> , "The opioid μ agonist/ δ antagonist DIPP-NH ₂ [Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats," <i>J. Med. Chem.</i> , 42(18):3520, 1999. |
| | C36 | Sharp and Yaksh, "Pain killers of the immune system," <i>Nat. Med.</i> , 3(8):831-832, 1997. |
| | C37 | Simon, "Opioid receptors and endogenous opioid peptides," <i>Medicinal Res. Rev.</i> , 11(4):357-374, 1991. |
| | C38 | Stevens <i>et al.</i> , "Potent and selective indolomorphinan antagonists of the kappa-opioid receptor," <i>J. Med. Chem.</i> , 43(14):2759-2769, 2000. |
| | C39 | Takemori and Portoghese, "Selective naltrexone-derived opioid receptor antagonists," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 32:239-269, 1992. |
| | C40 | Wei <i>et al.</i> , "N,N-diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel exceptionally selective, potent δ opioid receptor agonist with oral bioavailability and its analogues," <i>J. Med. Chem.</i> , 43(21):3895-905, 2000. |

25349931.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)